drugset / Trial / NCT00995787

Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea

NCT00995787

Phase 1 Completed 75 enrolled AstraZeneca
RandomizedSingle-groupSingle-blindTreatment

Summary

The primary aim of this study is to evaluate the safety and tolerability of AZD1656 in T2DM patients treated with metformin and sulfonylurea.

Timeline

Start
2009-10
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1656 Small molecule Oral